EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An mRNA vaccine for pancreatic cancer designed by applying in silico immunoinformatics and reverse vaccinology approaches

Md Habib Ullah Masum iD, Shah Wajed, Md Imam Hossain, Nusrat Rahman Moumi iD, Asma Talukder, Md Mijanur Rahman iD

PLOS ONE · 08.07.2024 · 19 (7) · e0305413

DOI: 10.1371/journal.pone.0305413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 08.07.2024. Verfasst von Md Habib Ullah Masum und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Noakhali Science and Technology University, Noakhali, Bangladesh. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Cancer Vaccines, Molecular Docking Simulation. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma is the most prevalent pancreatic cancer, which is considered a significant global health concern. Chemotherapy and surgery are the mainstays of current pancreatic cancer treatments; however, a few cases are suitable for surgery, and most of the cases will experience recurrent episodes. Compared to DNA or peptide vaccines, mRNA vaccines for pancreatic cancer have more promise because of their delivery, enhanced immune responses, and lower proneness to mutation. We constructed an mRNA vaccine by analyzing S100 family proteins, which are all major activators of receptors for advanced glycation end products. We applied immunoinformatic approaches, including physicochemical properties analysis, structural prediction and validation, molecular docking study, in silico cloning, and immune simulations. The designed mRNA vaccine was estimated to have a molecular weight of 165023.50 Da and was highly soluble (grand average of hydropathicity of -0.440). In the structural assessment, the vaccine seemed to be a well-stable and functioning protein (Z score of -8.94). Also, the docking analysis suggested that the vaccine had a high affinity for TLR-2 and TLR-4 receptors. Additionally, the molecular mechanics with generalized Born and surface area solvation analysis of the "Vaccine—TLR-2" (-141.07 kcal/mol) and "Vaccine—TLR-4" (-271.72 kcal/mol) complexes also suggests a strong binding affinity for the receptors. Codon optimization also provided a high expression level with a GC content of 47.04% and a codon adaptation index score 1.0. The appearance of memory B-cells and T-cells was also observed over a while, with an increased level of helper T-cells and immunoglobulins (IgM and IgG). Moreover, the minimum free energy of the mRNA vaccine was predicted at -1760.00 kcal/mol, indicating the stability of the vaccine following its entry, transcription, and expression. This hypothetical vaccine offers a groundbreaking tool for future research and therapeutic development of pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCancer VaccinesMolecular Docking SimulationHumansmRNA VaccinesComputational BiologyToll-Like Receptor 4VaccinologyToll-Like Receptor 2Computer SimulationRNA, MessengerImmunoinformatics

Substanzen

Cancer VaccinesmRNA VaccinesToll-Like Receptor 4Toll-Like Receptor 2RNA, MessengerTLR2 protein, human

Autor:innen und Institutionen

  • Department of Microbiology, Noakhali Science and Technology University, Noakhali, Bangladesh.
  • Microbiology, Cancer and Bioinformatics Research Group, Noakhali Science and Technology University, Noakhali, Bangladesh.
  • Infectiology: Biology of Infectious Diseases, Universite Paris-Saclay, Gif-sur-Yvette, France.
  • Medical Sciences, University of Central Lancashire, Preston, Lancashire, United Kingdom.
  • Department of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.
  • School of Pharmacy and Medical Sciences, and Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.

ORCID-Profile: Md Habib Ullah Masum, Nusrat Rahman Moumi, Md Mijanur Rahman

Zitieren

APA

Masum, M. H. U., Wajed, S., Hossain, M. I., Moumi, N. R., Talukder, A., & Rahman, M. M. (2024). An mRNA vaccine for pancreatic cancer designed by applying in silico immunoinformatics and reverse vaccinology approaches. PLOS ONE, 19(7), e0305413. https://doi.org/10.1371/journal.pone.0305413

Vancouver

Masum MHU, Wajed S, Hossain MI, Moumi NR, Talukder A, Rahman MM. An mRNA vaccine for pancreatic cancer designed by applying in silico immunoinformatics and reverse vaccinology approaches. PLOS ONE. 2024;19(7):e0305413. doi:10.1371/journal.pone.0305413

BibTeX
@article{Masum2024,
  author = {Masum, Md Habib Ullah and Wajed, Shah and Hossain, Md Imam and Moumi, Nusrat Rahman and Talukder, Asma and Rahman, Md Mijanur},
  title = {An mRNA vaccine for pancreatic cancer designed by applying in silico immunoinformatics and reverse vaccinology approaches},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {7},
  pages = {e0305413},
  doi = {10.1371/journal.pone.0305413}
}
Kostenlos starten →